Eledon Pharmaceuticals Investor Relations Material
Latest events
Study Update
Eledon Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Eledon Pharmaceuticals Inc
Access all reports
Eledon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to treat autoimmune diseases, organ transplantation, and neurodegenerative disorders. The company’s lead program involves developing treatments that target CD40L, a key immune system pathway involved in immune response regulation. By modulating this pathway, Eledon aims to develop therapies that prevent organ transplant rejection and treat autoimmune conditions without the need for long-term immunosuppression. The company's innovative approach seeks to address significant unmet medical needs in these therapeutic areas. The company is headquartered in Irvine, California, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
ELDN
Country
🇺🇸 United States